Definitions
Sorry, no definitions found. Check out and contribute to the discussion of this word!
Etymologies
Sorry, no etymologies found.
Support
Help support Wordnik (and make this page ad-free) by adopting the word laromustine.
Examples
-
Food and Drug Administration (FDA) related to a randomized Phase II/III trial of its oncology therapeutic Onrigin ™ (laromustine) Injection in combination with low-dose Ara-C (LDAC) in elderly patients with newly diagnosed acute myeloid leukemia
-
(OTC Bulletin Board: VION) announced that the New Drug Application (NDA) for its lead oncology therapeutic Onrigin (TM) (laromustine) Injection has received a standard review classification by the U.S.
-
Vion has two agents in clinical trials, Onrigin (TM) (laromustine) Injection and Triapine (R).
-
(OTC Bulletin Board: VION) announced that the New Drug Application (NDA) for its lead oncology therapeutic Onrigin (TM) (laromustine) Injection has received a standard review classification by the U.S.
-
The bankruptcy filing became necessary as a result of the Company's need to conduct an additional randomized trial of its lead anticancer compound, Onrigin (TM) (laromustine)
THE MEDICAL NEWS 2009
-
Food and Drug Administration (FDA), voted in favor of requiring Vion to complete a randomized study defining the efficacy and safety of the Company's lead oncology therapeutic Onrigin (TM) (laromustine) Injection prior to receiving regulatory approval from the FDA.
unknown title 2009
-
Vion has two agents in clinical trials, Onrigin (TM) (laromustine) Injection and Triapine (R).
-
Vion has two agents in clinical trials, Onrigin (TM) (laromustine) Injection and Triapine®.
unknown title 2009
-
VION. OB): Onrigin (laromustine) Injection (formerly known as Cloretazine or VNP40101M) NDA requesting approval as a single agent for remission induction treatment for patients age 60 and older with de novo poor-risk acute myeloid leukemia (
-
VION. OB): Onrigin (laromustine) Injection (formerly known as Cloretazine or VNP40101M) NDA requesting approval as a single agent for remission induction treatment for patients age 60 and older with de novo poor-risk acute myeloid leukemia (
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.